Titre :

Haploidentical hematopoietic stem cell transplant: how to choose the best donor? guidelines from the francophone society of bone marrow transplantation and cellular therapy (sfgm-tc)

Auteur(s) :

Dubois, Valerie [Auteur]
Amokrane, Kahina [Auteur]
Beguin, Yves [Auteur]
Bruno, Benedicte [Auteur]
Chevallier, Patrice [Auteur]
Delbos, Florent [Auteur]
Devillier, Raynier [Auteur]
Giannoli, Catherine [Auteur]
Guidicelli, Gwendaline [Auteur]
Harif, Mhamed [Auteur]
Loiseau, Pascale [Auteur]
Rouzaire, Paul-Olivier [Auteur]
Varlet, Pauline [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Nguyen, Stephanie [Auteur]

Titre de la revue :

Bulletin du cancer

Nom court de la revue :

Bull Cancer

Date de publication :

2019-10-02

ISSN :

1769-6917

Mot(s)-clé(s) en anglais :

DSA
Donor choice
Haploidentical
transplantation

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Haploidentical hematopoietic stem cell transplantation has been growing steadily since 2012. The SFGM-TC has twice published guidelines concerning T-cell repleted haploidentical grafts with high dose cyclophosphamide ...
Lire la suite >Haploidentical hematopoietic stem cell transplantation has been growing steadily since 2012. The SFGM-TC has twice published guidelines concerning T-cell repleted haploidentical grafts with high dose cyclophosphamide post-transplantation. The 2013 workshop recommended using the non-myeloablative Baltimore protocol with bone marrow and developed prospective protocols to evaluate these transplantations. The 2015 workshop reported improved results of reduced conditioning regimens in Hodgkin's lymphoma and intensive conditioning in myeloid hemopathies, and a similar outcome with 10/10 HLA matched donor with the same disease-risk score thus raising the question of the qualifier "alternative" for haploidentical transplants. The current work concerns the criteria for selecting the donor. The main criterion remains the absence of anti-HLA antibodies directed against the donor present in the recipient sera (DSA - Donor Specific Antibodies). In case of DSA and in the absence of an alternative donor, desensitization protocols exist. The other criteria are impossible to prioritize: age, sex, CMV, and blood type. The degree of relatedness and the number of HLA incompatibilities do not seem to be a criterion of choice. The 'ideal' donor would be a young man, CMV-matched, without major ABO incompatibility with a marrow transplant. There is insufficient data for the KIR-ligand and NIMA/NIPA mismatch. Peripheral stem cell grafts appear to yield more acute GVHD than bone marrow grafts after intensive conditioning, but with comparable survival rates. Based on the literature review, the comparison of haploidentical with unrelated donors encourages inclusion in existing national protocols randomizing these different donors.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:28:20Z